Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor phase 2 placebo-controlled study in primary biliary cholangitis with inadequate response to ursodeoxycholic acid
2016-003817-80Phase 2Completed
- Sponsor
- Genfit
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elafibranor in primary biliary cholangitis (PBC) (3 arms), sponsored by Genfit. Primary endpoint: Relative change from baseline in serum alkaline phosphatase. Started Mar 2017; status: completed.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2016-003817-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003817-80.